Khattar Jack A.'s Form 4 filing
Supernus Pharmaceuticals, Inc. (SUPN) · filed Nov 8, 2024
- Accession no.
- 0001628280-24-046663
- Filed
- Nov 8, 2024
- Trade date
- Nov 7, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.58M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Khattar Jack A.CIK 0001539937 | Director, Officer (President, CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2024 | Common Stock | MOption exerciseAcquired | +125,000 | $9.13 | +$1,141,250 | 1,051,172 | Direct | |
| Nov 7, 2024 | Common Stock | SSaleDisposed | −125,000 | $36.68 | −$4,585,000 | 926,172 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2024 | Common Stock | MOption exerciseDisposed | −125,000 | $0.00 | $0 | 125,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.